Home » Topics » Regulatory » EMA

EMA
RSS

EMA to begin review of Pfizer's tofacitinib MAA for rheumatoid arthritis

Nov. 22, 2011

CHMP recommends extended indication for Rebif in patients with early signs of MS

Nov. 21, 2011

Starpharma reaches agreement with EMA on phase III program for VivaGel

Nov. 21, 2011

AstraZeneca receives positive CHMP opinion for vandetanib

Nov. 21, 2011

EMA accepts Nuedexta MAA for filing

Nov. 18, 2011

AMT's gene therapy for hemophilia B given orphan drug status in Europe

Nov. 16, 2011

FDA and EMA accept Astellas' submissions for mirabegron

Nov. 15, 2011

Merck Sharp & Dohme withdraws MAA for fixed-dose combination of sitagliptin and pioglitazone

Nov. 15, 2011

EC withdraws marketing authorization for Ablavar

Nov. 14, 2011

Novartis presents key developments of third quarter 2011

Nov. 11, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...